Anakinra is an immunomodulatory drug that can reduce inflammation and joint pain, help reduce joint damage and improve joint function, and improve the quality of life of patients. This article details the indications, usage and dosage of Anakinra.

What are the indications of Anakinra?

Anakinra is used to treat a variety of inflammatory diseases, which can reduce inflammation and symptoms and delay the progression of the disease.

1. Active rheumatoid arthritis (RA)

Anakinra is suitable for patients with moderate to severe active rheumatoid arthritis who are 18 years of age or older and have used one or more anti-rheumatic drugs (DMARDs) to relieve rheumatoid arthritis but have not been effectively relieved.

The main therapeutic goal of Anakinra is to reduce the signs and symptoms of the disease and slow the progression of joint structural damage. Anakinra can be used alone or in combination with anti-rheumatic drugs that relieve rheumatoid arthritis other than tumor necrosis factor (TNF) blockers.

2. Cryopreservin-associated periodic syndrome (CAPS)

Anakinra is indicated for the treatment of a subtype of Cryopreservin-associated periodic syndrome, neonatal multisystem inflammatory disease (NOMID). Neonatal multisystem inflammatory disease is a rare genetic disease characterized by persistent skin symptoms, arthritis, neurological and visual problems, etc.

3. Interleukin-1 receptor antagonist deficiency (DIRA)

Anakinra is also indicated for the treatment of interleukin-1 receptor antagonist deficiency, a rare genetic disease. The condition often begins in infancy and persists throughout life. Patients often develop skin lesions such as redness, blisters and herpes. These skin symptoms are usually painful and itchy. In patients with IL-1 receptor antagonist deficiency, the immune system lacks interleukin-1 receptor antagonists, resulting in a severe inflammatory response. Patients may experience joint swelling, pain and limited movement. Arthritis can affect multiple joints, and the inflammatory response is more severe.

There are some studies and clinical trials exploring the use of Anakinra in other conditions, and preliminary studies have shown that Anakinra may have some therapeutic potential for other autoimmune diseases such as ankylosing spondylitis, juvenile idiopathic arthritis, inflammatory bowel disease, and psoriasis.

What is the dosage of Anakinra?

The dosage of Anakinra varies depending on the disease. The following is an introduction to the recommended dosage of Anakinra in different diseases.

1. Recommended dosage for active rheumatoid arthritis

The recommended dose of Anakinra for the treatment of rheumatoid arthritis is 100 mg per day, subcutaneously. Studies have shown that increasing the dose does not lead to a higher therapeutic response. It is recommended to administer the drug at approximately the same time each day to ensure a stable drug concentration.

2. Recommended dosage for cryopreservation protein-associated periodic syndrome and interleukin-1 receptor antagonist deficiency

The starting dose of Anakinra for both diseases is 1-2 mg/kg per day. The dose can be adjusted individually according to the condition, up to a maximum of 8 mg/kg per day. The dosage should be adjusted in increments of 0.5-1 mg/kg each time. It should be noted that for patients with multisystem inflammatory diseases (NOMID), it is generally recommended to administer the drug once a day, but it can also be divided into two doses a day.

Each syringe is for one use only, and a new syringe must be used for each administration, and unused medication should be discarded. For more information on the use of Anakinra, click for a free online consultation

Before using Anakinra, be sure to discuss it in detail with your doctor and use and adjust the dosage according to the doctor's instructions.